Psychiatry

A study found long-acting injectables reduced mean Young Mania Rating Scales scores in adolescents with bipolar mania from 33.8 at baseline to 21.7 at month 1.

Phase 2 data demonstrates the effectiveness of LB-102, developed with the potential to be the first-in-class benzamide antipsychotic, for adults with acute schizophrenia.

A study found intimate partner violence significantly lowers women's psychosocial well-being across finances, health, and relationships, but not men's.

Glutamatergic medications show promise for OCD & related disorders, reducing Y-BOCS scores.

A study found that the protein ADM significantly mediates loneliness' link to cardiovascular disease, stroke, dementia, and mortality, emphasizing loneliness’ health risks.

A recent study found individuals released from incarnation had a 10-fold greater prevalence of suicide mortality compared with the general population.

This Psychiatry Month in Review features promising phase 3 data, what is moving in the pipeline, and where the psychiatry field is heading into 2025.

Although the oral navacaprant 80 mg failed to bring statistically significant improvements in depression symptoms, the study showed females respond better than males.

This Year in Review features 2024 psychiatry highlights: FDA approvals, MDMA-assisted therapy setback, MM120 breakthrough, new CPT codes, and advances in schizophrenia treatments.

From groundbreaking therapies to ethical dilemmas, HCPLive’s top podcasts of 2024 delivered expert insights and human stories across medicine.

MDMA-assisted therapy, a source of hope for many, went on a tumultuous journey in 2024, going from historichype to setbacks.

A phase 3 trial shows promising data for brexpiprazole with sertraline for PTSD symptoms ahead of the supplemental new drug application’s PDUFA date in February 2024.

A study shows young adults with negative emotionality, particularly alienation, who experienced childhood adversities often experience more stressful life events in adulthood.

In a recent study, the prevalence of RLS occurred in 42.9% of participants with depression.

Efficacy and safety of brilaroxazine for schizophrenia sustained for > 1 year in open-label extension of RECOVER, announced by Reviva Pharmaceuticals.

A study finds that therapists deliver high-quality CBT in routine psychiatric care but found no evidence that therapist adherence and competence correlate to patient outcomes.

America's mental health crisis continues to escalate—what drives it, and what lies ahead in 2025? Hear insight from psychiatry and psychology experts.

A study shows constipation has a causal relationship with schizophrenia and MDD, but the relationship with schizophrenia may have limited clinical implications.

Patients with schizophrenia and COVID-19 both present dysregulated energy metabolism, explaining the high COVID-19 rates among those with schizophrenia.

A study found only 38% of patients in the large US academic health system screened for depression received antidepressants or mental health referrals.

A recent study found that loneliness among adults aged 50 – 80 increased from 2018 to 2022 and dropped in 2023 and 2024.

A study found 66.4% of participants with probable PTSD had a life stressor of unwanted sexual experiences.

This Month in Review captures November updates in the psychiatry pipeline.

A study found psilocybin therapy brings life-changing relief to depression symptoms triggered by clinicians’ frontline work during the COVID-19 pandemic.

A study revealed that people who are older, uneducated, unemployed, below the poverty line, publicly insured, rural, and male did not increase in psychotherapy use from 2018 to 2021.

Intra-Cellular Therapies announced they submitted a supplemental New Drug Application to the FDA for lumateperone (CAPLYTA) as an adjunctive therapy to antidepressants for MDD.

A study found patients with schizophrenia exhibiting violence, vs. those who don’t, have less gray matter volume in the frontal lobe and greater thyroid-stimulating hormone levels.

A new study supports mindfulness-based interventions as a complementary treatment for patients with schizophrenia spectrum disorders.

A study demonstrates many people with treatment-resistant schizophrenia do not comply with nutritional recommendations, which can contribute to increased mortality risk.

A study showed high-dose antipsychotics and benzodiazepines were linked to an increased mortality risk for those with schizophrenia. High-dose antidepressants lowered the risk.